OS Therapies reports 72.7% three-year survival rate for Herlystic in osteosarcoma trial
OS Therapies appoints Kerry Clem as Chief Commercial Officer
OS Therapies gets WHO approval for Herlystic brand name for OST-HER2
OSTX: OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
OS Therapies achieves FDA alignment on OST-HER2 Phase 3 trial design